Education
About Us
Working with TipRanks
Follow Us
Kyntra Bio (KYNB)
NASDAQ:KYNB
KYNB Stock Chart & Stats
$7.13
>-$0.01(-1.28%)
At close: 4:00 PM EST
$7.13
>-$0.01(-1.28%)
Day’s Range― - ―
52-Week Range$4.85 - $12.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)30.76K
Market Cap
$28.85M
Enterprise Value-$19.30M
Total Cash (Recent Filing)$88.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)0.2
Beta1.08
Next Earnings
May 11, 2026EPS Estimate
-3.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.51
Shares Outstanding4,046,827
10 Day Avg. Volume33,010
30 Day Avg. Volume30,760
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)7.93
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market Cap-0.67
Enterprise Value/Revenue-3.00
Enterprise Value/Gross Profit-3.95
Enterprise Value/Ebitda0.42
Forecast
1Y Price Target
$25.00Price Target Upside250.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-11.95
Revenue Forecast (FY)$6.10M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsAnalyst cites early-stage efficacy signals for FG-3246 versus a relevant comparator that provide clinical validation and reduce development risk for the lead program.
Imaging-enabled Patient SelectionAnalyst highlights the PET imaging agent FG-3180 as a tool to identify patients with higher target expression, which could enrich trials for responders and improve the likelihood of positive trial readouts.
Improved Tolerability StrategyAnalyst notes that prophylactic growth factor use appears to lower severe neutropenia rates, improving tolerability prospects for planned monotherapy studies.
Bears Say
Concentration RiskAnalyst highlights corporate realignment that concentrates resources on a single prostate cancer program, increasing company dependence on the lead candidate's success.
Peripheral Neuropathy DiscontinuationsAnalyst flags a high rate of treatment discontinuation driven by peripheral neuropathy, creating material tolerability concerns for the drug's payload and its overall clinical impact.
Safety RiskAnalyst warns that the heavy focus on safety and treatment-related adverse events means emerging safety issues could materially affect program outcomes and regulatory assessments.
Kyntra Bio News
KYNB FAQ
What was Kyntra Bio’s price range in the past 12 months?
Kyntra Bio lowest stock price was $4.85 and its highest was $12.60 in the past 12 months.
What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is $28.85M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s upcoming earnings report date is May 11, 2026 which is in 48 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on Mar 16, 2026. The company reported -$3.51 earnings per share for the quarter, beating the consensus estimate of -$3.885 by $0.375.
Is Kyntra Bio overvalued?
According to Wall Street analysts Kyntra Bio’s price is currently Undervalued.
Does Kyntra Bio pay dividends?
Kyntra Bio does not currently pay dividends.
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -3.36.
How many shares outstanding does Kyntra Bio have?
Kyntra Bio has 4,046,827 shares outstanding.
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of -$3.51 in its last earnings report, beating expectations of -$3.885. Following the earnings report the stock price went up 5.286%.
Which hedge fund is a major shareholder of Kyntra Bio?
Currently, no hedge funds are holding shares in KYNB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyntra Bio
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.
KYNB Company Deck
KYNB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call emphasizes substantial balance-sheet strengthening (sale, debt paydown), large full-year cost reductions, a clear cash runway into 2028, and encouraging early clinical signals for FG-3246/FG-3180 plus a promising roxadustat signal with orphan designation. However, the company faces sharp revenue declines, a weaker Q4 operating/profitability profile, statistical uncertainty around the imaging biomarker, dependency on upcoming trial readouts (2026–2027), and unresolved partnering/commercial strategies. Overall, the positives center on financing and promising early clinical data, while significant operational and commercialization uncertainties remain.View all KYNB earnings summariesKYNB Stock 12 Month Forecast
Average Price Target
$25.00
▲(250.63% Upside)
Technical Analysis
Ownership Overview
3.31% Insiders
22.64% Mutual Funds
10.91% Other Institutional Investors
59.27% Public Companies and
Individual Investors